ArticleJournal of visualized experiments : JoVE2014
A high throughput MHC II binding assay for quantitative analysis of peptide epitopes.
Article in Journal of visualized experiments : JoVE, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Gene modification: Exploring the potential in treating kidney diseases.Pharmacological research · 2026Review
- Article
- Immunogenicity of Protein Pharmaceuticals.Journal of pharmaceutical sciences · 2019Review
- Predicting Antigen Presentation-What Could We Learn From a Million Peptides?Frontiers in immunology · 2018Review
- HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response.Journal of immunology research · 2018Article
- Transcriptome analyses of immune tissues from three Japanese frogs (genus Rana ) reveals their utility in characterizing major histocompatibility complex class II.BMC genomics · 2017Article
- A cell-based high-throughput screening assay system for inhibitor compounds of antigen presentation by HLA class II molecule.Scientific reports · 2017Article
- Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads.Biotechnology and bioengineering · 2015Article
- Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.Chemistry & biology · 2015Article
- Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Molecular therapy. Methods & clinical development · 2015Article
- Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidate.PLoS computational biology · 2015Article
- Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.Cellular and molecular life sciences : CMLS · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Biochemical assays with recombinant human MHC II molecules can provide rapid, quantitative insights into immunogenic epitope identification, deletion, or design(1,2). Here, a peptide-MHC II binding assay is scaled to 384-well format. The scaled down protocol reduces reagent costs by 75% and is higher throughput than previously described 96-well protocols(1,3-5). Specifically, the experimental design permits robust and reproducible analysis of up to 15 peptides against one MHC II allele per 384-well ELISA plate. Using a single liquid handling robot, this method allows one researcher to analyze approximately ninety test peptides in triplicate over a range of eight concentrations and four MHC II allele types in less than 48 hr. Others working in the fields of protein deimmunization or vaccine design and development may find the protocol to be useful in facilitating their own work. In particular, the step-by-step instructions and the visual format of JoVE should allow other users to quickly and easily establish this methodology in their own labs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.